Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02385123
Recruitment Status : Recruiting
First Posted : March 11, 2015
Last Update Posted : December 3, 2018
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
This is an open label single arm study of longitudinal immunologic responses to influenza vaccine in healthy adult subjects. This study will enroll males and non-pregnant females, 18-49 years old. The subjects will be screened at enrollment with a history and physical exam and laboratory testing to ensure they are healthy enough to participate. Qualifying subjects will be vaccinated with an FDA approved seasonal inactivated influenza vaccine (IIV) according to the package insert. The study will enroll 10 healthy volunteers per vaccination season in years 1, 2 and 4 through 6 of this study, for a total enrollment of 50 subjects. The primary objective of the study is to characterize HA-specific plasmablasts and memory B cells after influenza vaccination.

Condition or disease Intervention/treatment Phase
Influenza Influenza Immunisation Biological: Influenza Virus Vaccine Inactivated Phase 4

Detailed Description:
This is an open label, single arm, study of longitudinal immunologic responses to influenza vaccine in healthy adult subjects. This study will enroll males and non-pregnant females, 18-49 years old. The study duration is 6 years and participant duration of 180 days. The subjects will be screened at enrollment with a history and physical exam and laboratory testing to ensure they are healthy enough to participate. Qualifying subjects will be vaccinated with an FDA approved seasonal inactivated influenza vaccine (IIV) according to the package insert. Approximately 450 ml of blood will be collected for the research assays during the course of the study. Specifically, 16 ml will be collected for screening; 48ml will be collected at enrollment; 96ml will be collected at visit days 7 and 14; and 64 ml will be collected at 28, 90, and 180 days post vaccination. The study will enroll 10 healthy volunteers per vaccination season in years 1, 2, and 4 through 6 of this study, for a total enrollment of 50 subjects. Individuals who complete the study will be given the option to re-enroll in subsequent years as long as they continue to meet all inclusion/exclusion criteria. Re-enrolling subjects will be re-consented, given new subject identifiers, and counted towards the enrollment number goal for each year of participation. The primary objective of the study is to characterize HA-specific plasmablasts and memory B cells after influenza vaccination and secondary objective investigate the longevity of humoral immunity to influenza virus in humans.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
Actual Study Start Date : April 1, 2015
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : April 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: Seasonal flu vaccine
0.5 ml of seasonal inactivated influenza vaccine (IIV) will be administered intramuscularly (IM) on day 0 of each study season. The study will enroll 10 subjects each season, in years 1, 2, 4 ,5, and 6 of the study for a total of n=50.
Biological: Influenza Virus Vaccine Inactivated
A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.




Primary Outcome Measures :
  1. Percentage of subjects achieving seroconversion (pre-vaccination Hemagglutination Inhibition (HI) titer < 1:10 and a post-vaccination HI titer > 1:40 or a pre-vaccination HI titer > 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer) [ Time Frame: Day 28 ]
  2. Percentage of subjects achieving seroconversion (pre-vaccination Hemagglutination Inhibition (HI) titer < 1:10 and a post-vaccination HI titer > 1:40 or pre-vaccination HI titer > 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer) [ Time Frame: Day 0 ]

Secondary Outcome Measures :
  1. Endpoint IgG titers for serum antibody responses directed against the hemagglutinin (HA) head regions [ Time Frame: Day 0 ]
  2. Endpoint IgG titers for serum antibody responses directed against the hemagglutinin (HA) head regions [ Time Frame: Day 180 ]
  3. Endpoint IgG titers for serum antibody responses directed against the hemagglutinin (HA) head regions [ Time Frame: Day 28 ]
  4. Endpoint IgG titers for serum antibody responses directed against the hemagglutinin (HA) stem regions [ Time Frame: Day 0 ]
  5. Endpoint IgG titers for serum antibody responses directed against the hemagglutinin (HA) stem regions [ Time Frame: Day 180 ]
  6. Endpoint IgG titers for serum antibody responses directed against the hemagglutinin (HA) stem regions [ Time Frame: Day 28 ]
  7. Expression of human influenza-specific monoclonal antibodies from plasmablasts [ Time Frame: Day 7 ]
  8. Frequency of hemagglutinin (HA) head-specific IgG secreting memory B cells per total IgG secreting cells [ Time Frame: Day 0 ]
  9. Frequency of hemagglutinin (HA) head-specific IgG secreting memory B cells per total IgG secreting cells [ Time Frame: Day 180 ]
  10. Frequency of hemagglutinin (HA) head-specific IgG secreting memory B cells per total IgG secreting cells [ Time Frame: Day 28 ]
  11. Frequency of hemagglutinin (HA) stem-specific IgG secreting memory B cells per total IgG secreting cells [ Time Frame: Day 0 ]
  12. Frequency of hemagglutinin (HA) stem-specific IgG secreting memory B cells per total IgG secreting cells [ Time Frame: Day 180 ]
  13. Frequency of hemagglutinin (HA) stem-specific IgG secreting memory B cells per total IgG secreting cells [ Time Frame: Day 28 ]
  14. Function of human influenza- specific monoclonal antibodies assessed by virus neutralization assay [ Time Frame: Day 7 ]
  15. Function of human influenza-specific monoclonal antibodies assessed by Enzyme-Linked Immunosorbent Assay (ELISA) [ Time Frame: Day 7 ]
  16. Function of human influenza-specific monoclonal antibodies assessed by Hemagglutination Inhibition (HAI) assay [ Time Frame: Day 7 ]
  17. Influenza hemagglutinin head-specific memory B-cells level [ Time Frame: Day 0 ]
  18. Influenza hemagglutinin head-specific memory B-cells level [ Time Frame: Day 180 ]
  19. Influenza hemagglutinin head-specific memory B-cells level [ Time Frame: Day 28 ]
  20. Influenza hemagglutinin serum antibody level [ Time Frame: Day 0 ]
  21. Influenza hemagglutinin serum antibody level [ Time Frame: Day 180 ]
  22. Influenza hemagglutinin serum antibody level [ Time Frame: Day 28 ]
  23. Influenza hemagglutinin stem-specific memory B-cells level [ Time Frame: Day 0 ]
  24. Influenza hemagglutinin stem-specific memory B-cells level [ Time Frame: Day 180 ]
  25. Influenza hemagglutinin stem-specific memory B-cells level [ Time Frame: Day 28 ]
  26. Plasmablast responses against hemagglutinin (HA) head antigens assessed by direct ex vivo enzyme-linked immunospot (ELISPOT) [ Time Frame: Day 7 ]
  27. Plasmablast responses against hemagglutinin (HA) stem anitgens assessed by direct ex vivo enzyme-linked immunospot (ELISPOT) [ Time Frame: Day 7 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female subjects between 18 and 49 years of age, inclusive
  2. Subjects capable of providing written informed consent prior to initiation of any study procedures. Subjects able to understand and comply with planned study procedures and be available for all study visits
  3. Screening labs within normal limits per the local laboratory normal ranges or considered to be not clinically significant by the investigator. Normal laboratory ranges are as listed below:

    A. Hematology:

    • Hemoglobin: Male- 12.9-16.1 gm/dL, Female- 11.4-14.4 gm/dL
    • White blood cells (WBC): Male- 4.2-9.2/uL, Female- 4-10/uL
    • Platelet count: 150-400/uL

    B. Chemistries:

    • Kidney function:Glomerular filtration rate (GFR) > / = 60 mL/min/1.73 m^2;
    • Liver enzymes: Albumin > / = 3.5 g/dL; ALT <66 U/L; AST <62 U/L
  4. Subjects who have not received the seasonal influenza vaccine in the current flu season and are not suspected to have had an influenza infection in the current flu season
  5. Female subjects of child bearing potential must have a negative urine pregnancy test at the screening visit, enrollment visit and all subsequent study visits longer than 14 days since the last pregnancy test

Exclusion Criteria:

  1. Known infection with HIV, HCV, or HBV. This information will be obtained verbally from the patient.
  2. If female, active pregnancy or breast-feeding or plans to become pregnant during study participation.
  3. Chronic medical conditions that cause immunodeficiency or that require medications which could alter immune function such as immunosuppressants and immunoenhancers.
  4. Have any medical disease or condition that, in the opinion of the site principal investigator or appropriate sub-investigator, is a contraindication to study participation. This includes any chronic medical disease or condition, defined as persisting 3 months (defined as 90 days) or longer, that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this study
  5. Have an acute illness, as determined by the site principal investigator or appropriate sub-investigator, within 72 hours prior to study vaccination. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site principal investigator or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.
  6. Persons taking anticoagulants, long-term aspirin therapy, or long-term systemic steroids (greater than 3 months in the past 12 months and any within 30 days).
  7. Have known hypersensitivity or allergy to eggs, egg or chicken protein or other components of the study vaccine;
  8. Have a known latex allergy;
  9. Have a history of severe reactions following previous immunization with licensed influenza virus vaccines
  10. Have a history of Guillain-Barre syndrome
  11. Subjects who had or are suspected to have had an influenza infection in the current influenza season
  12. Subjects who, at screening, have abnormal vital signs and/or physical exam, including a temperature > / = 38.0 C, Systolic blood pressure < / =90 or > / =160 mmHg, pulse < / = 60 or > 110 beats per minute, new rash, signs of infection.
  13. Subjects who have already received the seasonal influenza vaccine in the current influenza vaccination season.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02385123


Contacts
Layout table for location contacts
Contact: Aneesh K Mehta 14047278435 aneesh.mehta@emory.edu

Locations
Layout table for location information
United States, Georgia
Emory University Hospital - W. Dean Warren General Clinical Research Center (GCRC) Recruiting
Atlanta, Georgia, United States, 30322-1059
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)

Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT02385123     History of Changes
Other Study ID Numbers: 14-0071
HHSN272201400004C
First Posted: March 11, 2015    Key Record Dates
Last Update Posted: December 3, 2018
Last Verified: November 21, 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
ex-vivo
Healthy Volunteers
Immune Response
Influenza
plasmablasts
Vaccine

Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs